The DFA Discussion, page-80

This will irreparably damage whatever credibility OPT has left. The data will be severely compromised by bias, rendering it unusable, let alone sufficient for regulatory approval of a drug once projected to generate billions in revenue. The bullish case is effectively dead, and voluntary administration now appears to be the most likely outcome.